LyrArc Article Gist
Sales have declined and share price dropped by 40% since J.C. Penney's new CEO, Ron Johnson, tried to bring strategies that worked with Apple to the U.S. department store.

LyrArc Article Gist
The Senate votes to approve the US-Russia Start treaty for nuclear weapons reduction.

LyrArc Article Gist
The redesigning of suburban office space to fit remote work and hybrid work needs in the US.

LyrArc Article Gist
Over half of the companies in the US plan to hire in 2025. Considerable uncertainty prevailed in 2024 about hiring, this is clearing up in 2025 with a new administration keen on boosting growth.

LyrArc Article Gist
Issues of cost of living and higher taxes in states in the northeastern US and California vs the lower taxes and lower cost of living in the Southern States of the US. Whose side each of the two main parties are on in the US has switched in the period since Harry Truman and FDR in the 1940's. The Republicans represent small business and the less educated in society, the Democrats represent the more educated, affluent sections, and women, the black minority, with Hispanics divided between the two parties. Unions are now neutral and workers in factories lean more towards Republicans. On health care there is a failure for both parties. Both parties have failed miserably with all the lobbying creating obstacles-- to provide cost of living in healthcare. In comparing healthcare and the wealth of societies, it can now be noted that a well funded healthcare system with medicine within reach of the entire population of 1.4 billion people in a poor country like India does better than that of a rich society like the US with 350 million people. This makes a huge difference in the quality of life. Infrastructure investments in relatively far less affluent countries like China and now India make it possible to have better conditions of living relative to the US with infrastructure and transportation from the 19th century still awaiting rebuilding. ...

LyrArc Article Gist
FDA's approach to Eli Lilly's drug Prasgrel which is more effective than Plavix for preventing heart attacks but can lead to fatal bleeding in some patients. The other side of the picture is that 30% of patients are not suited for Plavix, and these patients could have an alternative. In weighing the risks and the benefits, and of letting some patients who may be suited to Prasugrel have access to the drug, the FDA has to find the right approach. An FDA panel was set to recommend whether to approve the drug and under what conditions.